ONC · BeOne Medicines Ltd.

BeOne Medicines Ltd.'s announcement of accelerated FDA approval for BEQALZI™ (sonrotoclax) represents a major milestone as the first and only BCL2 inhibitor approved for relapsed or refractory mantle cell lymphoma (R/R MCL) in the U.S., and the first new BCL2 inhibitor in a decade. This approval targets adult patients after at least two lines of systemic therapy, including a BTK inhibitor, addressing a challenging setting where outcomes are poor post-relapse. Efficacy data from the Phase 1/2 BGB-11417-201 study (NCT05471843), presented at the 67th ASH meeting, showed an overall response rate of 52% (95% CI 42-62), complete response rate of 16% (95% CI 9.1-24.0), median time to response of 1.9 months, and median duration of response of 15.8 months (95% CI 7.4-NE) at a median follow-up of 11.9 months. The drug was generally well-tolerated as monotherapy. Continued approval depends on verifying clinical benefit in the ongoing confirmatory CELESTIAL-RRMCL trial (NCT06742996). BEQALZI also holds approvals in China for R/R MCL and CLL/SLL, with data under review by the EMA and others. Additional designations include FDA Breakthrough Therapy for MCL, Fast Track for Waldenström macroglobulinemia, and Orphan Drug for multiple indications. Safety highlights include risks of tumor lysis syndrome (7% incidence with ramp-up), serious infections (14%), and neutropenia (18% Grade 3-4), with specific contraindications and monitoring requirements. This positions BEQALZI as a foundational therapy, potentially improving efficacy, tolerability, and convenience over prior BCL2 inhibitors, enhancing BeOne's oncology portfolio.